PMA supplement
P110033 S065: Juvéderm Volux XC
FDA PMA supplement · Panel Track · Allergan
Key facts
| Original PMA | P110033 |
|---|---|
| Supplement number | S065 |
| Supplement type | Panel Track |
| Reason for the supplement | Labeling Change - Indications/instructions/shelf life/tradename |
| Trade name | Juvéderm Volux XC |
| Generic name | Implant, dermal, for aesthetic use |
| Applicant | Allergan |
| Product code | LMH |
| Received date | Aug 30, 2021 |
| Decision date | Jul 29, 2022 |
| Docket number | 22M-1793 |
| Notice date | Aug 4, 2022 |
At a glance
- No Expedited review granted
- Yes Approval order on file
- Yes Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: